Akava receives Orphan Drug Designation status for AKV9

July 6, 2022
Akava Therapeutics, LLC announces that on July 6, 2022, orphan drug designation (ODD) status was received for AKV9 for the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food...
Read More

This time around, Lyrica’s inventor is developing his Northwestern discoveries at his own biotech

May 26, 2022
Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval...
Read More

NU‑9 improves health of ­hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone

March 30, 2022
A paper has recently been published demonstrating that AKV9 improves the health of mutant SOD1 mouse upper motor neurons in vitro much better than the FDA-approved ALS drugs riluzole and edaravone, and the combination of AKV9 with either of those drugs provides an additive effect.
Read More

AKAVA Founder, Richard B. Silverman receives 2021 Tetrahedron Prize

August 30, 2021
Our Founder, Richard B. Silverman, was selected to receive the 2021 Tetrahedron Prize for Creativity in Organic Chemistry and will present a lecture at the Tetrahedron Symposium in Lisbon, Portugal this June.
Read More